Epigenetic patterns of the retinoic acid receptor β2 promoter in retinoic acid-resistant thyroid cancer cells

Oncogene

Volumn 26, Issue 27, 2007, Pages 4018-4024

  Cras, A ^a   Darsin Bettinger, D ^a   Balitrand, N ^a   Cassinat, B ^a,b   Soulie A ^a   Toubert, M E ^a,b   Delva, L ^a   Chomienne, C ^a,b  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Histone acetylation; RA resistance; RAR 2 promoter; Thyroid cells

Indexed keywords

HISTONE H3; HISTONE H4; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; TRICHOSTATIN A;

ACETYLATION; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA METHYLATION; DRUG RESPONSE; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; TRANSACTIVATION;

ACETYLATION; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; PROMOTER REGIONS (GENETICS); RECEPTORS, RETINOIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRETINOIN;

EID: 34249977889     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210178     Document Type: Article

References (36)

1. Bastie JN, Balitrand N, Guidez F, Guillemot I, Larghero J, Calabresse C et al. (2004). 1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol Endocrinol 18: 2685-2699.
2. Carpentier A, Balitrand N, Rochette-Egly C, Shroot B, Degos L, Chomienne C. (1997). Distinct sensitivity of neuroblastoma cells for retinoid receptor agonists: evidence for functional receptor heterodimers. Oncogene 15: 1805-1813.
3. Carpentier AF, Leonard N, Lacombe J, Zassadowski F, Padua RA, Degos L et al. (1999). Retinoic acid modulates RAR alpha and RAR beta receptors in human glioma cell lines. Anticancer Res 19: 3189-3192.
4. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P et al. (2000). Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 14: 324-328.
5. Chomienne C, Balitrand N, Ballerini P, Castaigne S, De Thé H, Degos L. (1991). All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. J Clin Invest 88: 2150-2154.
6. Cote S, Sinnett D, Momparler RL. (1998). Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9: 743-750.
7. De Thé H. (1996). Altered retinoic acid receptors. FASEB J 10: 955-960.
8. De Thé H, Vivanco-Ruiz MM, Tiollais P, Stunnenberg H, Dejean A. (1990). Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene. Nature 343: 177-180.
9. De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Lauro R, Fusco A et al. (1998). Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ 9: 97-103.
10. Delva L, Bastie JN, Rochette-Egly C, Kraiba R, Balitrand N, Despouy G et al. (1999). Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. Mol Cell Biol 19: 7158-7167.
11. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. (1999). Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 141: 443-457.
12. Goretzki PE, Frilling A, Simon D, Roeher HD. (1990). Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118: 48-63.
13. Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R et al. (1998). Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39: 1903-1906.
14. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. (1998). A National Cancer Data Base report on 53 856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83: 2638-2648.
15. Idres N, Marill J, Flexor MA, Chabot GG. (2002). Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers. J Biol Chem 277: 31491-31498.
16. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S et al. (1999). Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84: 3228-3234.
17. Mazzaferri EL, Jhiang SM. (1994). Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428.
18. Momparler RL. (2003). Cancer epigenetics. Oncogene 22: 6479-6483.
19. Niles RM. (2004). Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 555: 81-96.
20. Pasca di Magliano M, Di Lauro R, Zannini M. (2000). Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97: 13144-13149.
21. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. (1995). Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80: 1488-1492.
22. Rochaix P, Monteil-Onteniente S, Rochette-Egly C, Caratero C, Voigt JJ, Jozan S. (1998). Reduced expression of retinoic acid receptor beta protein (RAR beta) in human papillary thyroid carcinoma: immunohistochemical and Western blot study. Histopathology 33: 337-343.
23. Rochette-Egly C. (2005). Dynamic combinatorial networks in nuclear receptor-mediated transcription. J Biol Chem 280: 32565-32568.
24. Rousselot P, Hardas B, Patel A, Guidez F, Gaken J, Castaigne S et al. (1994). The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 9: 545-551.
25. Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D et al. (1998). Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 76: 368-376.
26. Schmutzler C, Kohrle J. (2000). Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 10: 393-406.
27. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J. (1997). Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5rat thyroid cells. Biochem Biophys Res Commun 240: 832-838.
28. Schreck R, Schnieders F, Schmutzler C, Kohrle J. (1994). Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 79: 791-798.
29. Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R et al. (2002). Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29: 775-782.
30. Suh YA, Lee HY, Virmani A, Wong J, Mann KK, Miller WH et al. (2002). Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res 62: 3945-3949.
31. Sun SY, Lotan R. (2002). Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41: 41-55.
32. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D et al. (2000). Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92: 1303-1307.
33. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M et al. (2000). Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 92: 826-832.
34. Wynford-Thomas D. (1993). In vitro models of thyroid cancer. Cancer Surv 16: 115-134.
35. Youssef EM, Estecio M, Issa JP. (2004a). Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther 3: 82-86.
36. Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L et al. (2004b). Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res 10: 1733-1742.